Xyrem® (sodium oxybate) – Expanded indication
October 29, 2018 - Jazz Pharmaceuticals announced the FDA approval of Xyrem (sodium oxybate), for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy.
Download PDF
